Findings showed a 13.6% reduction in body weight in the semaglutide 25mg group compared with a 2.2% reduction in the placebo group.

In the first head-to-head comparison of leading incretin-based therapies, Eli Lilly’s dual GIP/GLP-1 receptor agonist ...

A Comprehensive Review of MEDVi’s Personalized GLP-1 Weight Loss Solutions Featuring Affordable Compounded Semaglutide and Tirzepatide Delivered via TelehealthNew York, May 10, 2025 (GLOBE NEWSWIRE) - ...

Using semaglutide injections, scientists were able to reverse life-threatening cases of liver disease in a new clinical trial published in The New England Journal of Medicine. Semaglutide ...

Using semaglutide injections, scientists were able to reverse life-threatening cases of liver disease in a new clinical trial published in The New England Journal of Medicine. Semaglutide ...

The risk for ocular problems linked to different formulations of semaglutide appear to vary, according to a new study, which ...

Semaglutide effectively treats liver disease in two thirds of patients, new research has found. Results from the ESSENCE phase 3 clinical trial published today in the New England Journal of ...

Interim results from the Phase III ESSENCE trial published in The New England Journal of Medicine show once-weekly ...

25 mg oral formulation of Wegovy ® (semaglutide) for chronic weight management in adults living with obesity or overweight with one or more comorbid conditions and to reduce the risk of major ...

Findings showed a 13.6% reduction in body weight in the semaglutide 25 mg group compared with a 2.2% reduction in the placebo group. The Food and Drug Administration (FDA) has accepted for review ...